13 July 2017

Director/PDMR Dealing

'This announcement contains inside information.'

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that Options over ordinary shares of 1p each, as noted below in the Company ("Ordinary Shares") were granted on 12 July 2017.

The Options have an exercise period of ten years from grant and have an exercise price per Option of 5.25p. The Options vest in full after the normal vesting date of 12 July 2020, upon the closing middle market price per Ordinary Share achieving 10p and positive cash flow from operations being sustained for a period of six months.

Director/PDMR Position Number of
Ordinary
Shares options granted
Jamal Rushdy Chief Executive Officer 1,700,000
Gillian Black Chief Financial Officer 1,700,000
Christian Wattengel PDMR / VP Global R&D 500,000

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name
  1. Jamal Rushdy
  2. Gillian Black
  3. Christian Wattengel
2 Reason for the notification
a) Position/status
  1. Chief Executive Officer
  2. Chief Financial Officer
  3. PDMR / VP Global R&D
b) Initial notification / Amendment Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Collagen Solutions plc
b) LEI N/A
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Option to acquire 1p ordinary shares in Collagen Solutions Plc

N/a
b) Nature of the transaction Grant of options
c) Price(s) and volume(s)
Price (exercise) Volume(s)
1. 5.25p per share 1,700,000
2. 5.25p per share 1,700,000
3. 5.25p per share 500,000
d) Aggregated information
- Aggregated volume
- Price

N/A
N/A
e) Date of the transaction 12 July 2017
f) Place of the transaction Outside a trading venue

 

About Collagen Solutions:  

Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.

 

Enquiries: 

Collagen Solutions Plc
Jamal Rushdy, Chief Executive Officer
Gill Black, Chief Financial Officer
Contact via Walbrook
   
Cenkos Securities plc (Nominated Adviser and Broker)
Stephen Keys
Steve Cox 
Callum Davidson
Tel: 0207 397 8900
   
Walbrook PR
Mike Wort
Anna Dunphy
Tel: 020 7933 8780 or collagen@walbrookpr.com
Mob: 07900 608 002
Mob: 07876 741 001